IPM is studying and testing a number of potential drugs and innovative drug delivery methods, among them:

	Dapivirine – Vaginal Gel: IPM is conducting microbicide safety trials at clinical sites in Belgium, Rwanda, South Africa and Tanzania to test the safety and acceptability of dapivirine (TMC120 gel), an antiretroviral compound designed to prevent or interrupt HIV replication in human cells.
	Dapivirine – Vaginal Ring Delivery: IPM is researching dapivirine’s use in an innovative vaginal ring delivery system following two successful safety studies (IPM001 in 2004 and IPM008 in 2005) which showed the rings to be a viable drug delivery method. An effective vaginal ring delivery system could be highly beneficial to women by offering them extended HIV protection, possibly for weeks or even months.
	Other Drugs: IPM is developing additional compounds licensed from Merck & Co, Inc. and Bristol-Myers Squibb and is continuing to expand its pipeline so that more clinical trials in the future will be conducted using new drugs and/or combinations of drugs.

>> View a complete list of IPM clinical trials and their status

Partnering with Local Communities

Clinical research must be conducted in full partnership with host-country communities. In all aspects of clinical trial planning, IPM works closely with local partners on protocol development, recruitment and implementation. Additionally, every IPM-sponsored trial site works with a community advisory board to learn about community perspectives and to engage community members as partners. IPM works closely with local policy makers to foster ownership and commitment to the clinical trial process for all of its clinical trials.

Guidelines for Conducting Clinical Trials

IPM has also developed comprehensive guidelines for the conduct of its clinical trials through a rigorous ethical and peer review process. These guidelines detail a commitment to provide all study participants with ongoing risk reduction counselling, male and female condoms, treatment for those who become infected with HIV during the course of the trial, and treatment and compensation in the unlikely event physical harm results from trial participation. For more information, read the Guidelines for the Conduct of IPM’s Clinical Trials.

>> Read IPM’s Issue Brief on Clinical Trials

IPM Clinical Trials
(as of October 2008)

Study Protocol	Study Name & Location	Number of volunteers	Status & Reports
IPM 001	Dapivirine intravaginal ring safety Belgium	12	Completed, 2004-05 Poster (CROI 2007)
IPM 003	Dapivirine gel safety Rwanda, South Africa, Tanzania	112	Completed, 2005-06 Abstract (M2008)
IPM 004	Dapivirine gel PK South Africa	18	Completed, 2005-06 Abstract (M2008)
IPM 005B	Dapivirine gel safety Belgium	36	Completed, 2005-06 Abstract (ICAAC 2007)
IPM 007	Seroconverter protocol TBD	N/A	Planned
IPM 008	Dapivirine intravaginal ring safety Belgium	13	Completed, 2005 Abstract (AIDS 2006)
IPM 009	Dapivirine efficacy TBD	TBD	Planned
IPM 010	Dapivirine gel male tolerance TBD	TBD	Planned
IPM 011	Placebo intravaginal ring safety & acceptability South Africa, Tanzania Kenya	200	Ongoing, 2007-08 Follow-up
IPM 012	Dapivirine gel PK Belgium	36	Data analysis
IPM 013	Dapivirine intravaginal ring PK Belgium	96	Planned
IPM 014A	Dapivirine gel safety Kenya, Malawi, Rwanda, South Africa, Tanzania	320	Planned
IPM 014B	Dapivirine gel safety Kenya, Malawi, Rwanda, South Africa, Tanzania, Zambia	320	Planned
IPM 015	Dapivirine intravaginal ring safety Kenya, Malawi, Rwanda, South Africa, Tanzania, Zambia	280	Planned
IPM 018	Dapivirine intravaginal ring PK Belgium	24	Completed, 2007 Poster (CROI 2008)
IPM 020	Dapivirine gel safety United States	150	Planned
IPM 021	Dapivirine intravaginal ring safety Germany, Netherlands, United Kingdom	120	Planned
IPM 022	Smart applicator pilot South Africa, United States	113	Planned
IPM 023	Dapivirine gel safety Belgium	72	Planned